As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
The Anatolian Journal of Cardiology
The role of rivaroxaban in left ventricular thrombi [Anatol J Cardiol]
The role of rivaroxaban in left ventricular thrombi
Mahmoud Abdelnaby1, Abdallah Almaghraby2, Ola Abdelkarim2, Yehia Saleh3, Basma Hammad4, Haitham Badran51Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, University of Alexandria; Alexandria-Egypt 2Department of Cardiology, Faculty of Medicine, University of Alexandria; Alexandria-Egypt 3Department of Internal Medicine, Michigan State University; East Lansing, Michigan-United States of America 4Department of Cardiology, Massachusetts General Hospital; Boston-United States of America 5Department of Cardiology, Ain Shams University; Cairo-Egypt Keywords: Left ventricular apical thrombi, Novel Oral Anticoagulants (NOACs), Rivaroxaban, Vitamin K Antagonist (VKA), Acute Coronary Syndromes (ACS), Dual Antiplatelet Therapy (DAPT)
Mahmoud Abdelnaby, Abdallah Almaghraby, Ola Abdelkarim, Yehia Saleh, Basma Hammad, Haitham Badran. The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol. 2019; 21(1): 47-50
Corresponding Author: Abdallah Almaghraby, Egypt Manuscript Language: English